EMvision Medical Devices Ltd. (AU:EMV)
ASX:EMV
Top Page
EMvision Medical Devices Ltd.
(Sydney:EMV)
Select Model
Select Model
Rating:44Neutral
Price Target:
AU$1.50
▼(-15.25% Downside)
Action:ReiteratedDate:10/29/25
The overall stock score of 44 reflects significant financial challenges, including declining revenues and persistent losses. The technical analysis indicates weak momentum, and the valuation is unattractive due to a negative P/E ratio and no dividend yield. These factors collectively suggest a cautious outlook for the stock.
Positive Factors
Proprietary portable brain‑imaging technology
EMvision’s portable electromagnetic brain‑imaging focus is a durable strategic asset: the technology targets pre-hospital and bedside stroke/TBI diagnosis where speed matters. Structural demand for faster, point‑of‑care imaging and specialized modality differentiation creates long-term commercial pathways if regulatory and reimbursement progress continues.
Negative Factors
Steep revenue decline
A 37% year-over-year revenue contraction is a durable red flag: it signals weak market adoption or commercialization setbacks. Sustained top-line decline erodes scale economies, limits ability to fund clinical and regulatory programs internally, and undermines the pathway to profitable operations unless revenue inflection is achieved.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary portable brain‑imaging technology
EMvision’s portable electromagnetic brain‑imaging focus is a durable strategic asset: the technology targets pre-hospital and bedside stroke/TBI diagnosis where speed matters. Structural demand for faster, point‑of‑care imaging and specialized modality differentiation creates long-term commercial pathways if regulatory and reimbursement progress continues.
Read all positive factors
EMvision Medical Devices Ltd. (EMV) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$144.05M
Dividend YieldN/A
Average Volume (3M)120.98K
Price to Earnings (P/E)―
Beta (1Y)0.67
Revenue GrowthN/A
EPS Growth-257.32%
CountryAU
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.04
Shares Outstanding92,938,610
10 Day Avg. Volume127,185
30 Day Avg. Volume120,982
Financial Highlights & Ratios
PEG Ratio-0.07
Price to Book (P/B)16.01
Price to Sales (P/S)29.42
P/FCF Ratio-18.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$3.15Price Target Upside77.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.1
Revenue Forecast (FY)AU$6.00M
EMvision Medical Devices Ltd. Business Overview & Revenue Model
Company Description
EMvision Medical Devices Limited, a medical device company, engages in the research, development, and commercialization of imaging and diagnostic technology products. It develops a portable brain scanner for stroke diagnosis, monitoring, as well a...
How the Company Makes Money
null...
EMvision Medical Devices Ltd. Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
45
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.56M | 5.05M | 11.22M | 6.97M | 4.36M | 1.70M |
| Gross Profit | 1.35M | 5.05M | 11.22M | 6.63M | 4.12M | 1.58M |
| EBITDA | -13.27M | -8.71M | -8.35M | -5.99M | -7.84M | -9.56M |
| Net Income | -10.20M | -9.81M | -2.73M | -3.87M | -6.11M | -8.40M |
Balance Sheet | ||||||
| Total Assets | 24.94M | 15.57M | 23.97M | 11.52M | 8.51M | 10.77M |
| Cash, Cash Equivalents and Short-Term Investments | 17.56M | 10.53M | 18.67M | 9.97M | 6.80M | 9.69M |
| Total Debt | 4.02M | 3.53M | 2.90M | 3.04M | 737.86K | 213.17K |
| Total Liabilities | 5.20M | 6.29M | 5.46M | 6.40M | 1.43M | 720.01K |
| Stockholders Equity | 19.74M | 9.28M | 18.52M | 5.12M | 7.08M | 10.05M |
Cash Flow | ||||||
| Free Cash Flow | -9.02M | -7.89M | -6.29M | 646.86K | -3.97M | -4.62M |
| Operating Cash Flow | -8.94M | -7.84M | -5.99M | 834.15K | -3.78M | -4.49M |
| Investing Cash Flow | -78.32K | -50.37K | -302.41K | -187.29K | -191.12K | -127.25K |
| Financing Cash Flow | 12.96M | -258.34K | 15.00M | 2.52M | 1.08M | 8.90M |
EMvision Medical Devices Ltd. Technical Analysis
Negative
1.77
Price Trends
1.72
Negative
1.77
Negative
1.81
Negative
Market Momentum
-0.05
Positive
36.61
Neutral
53.13
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EMV, the sentiment is Negative. The current price of 1.77 is above the 20-day moving average (MA) of 1.62, above the 50-day MA of 1.72, and below the 200-day MA of 1.81, indicating a bearish trend. The MACD of -0.05 indicates Positive momentum. The RSI at 36.61 is Neutral, neither overbought nor oversold. The STOCH value of 53.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EMV.
EMvision Medical Devices Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | AU$196.92M | -47.06 | -3.80% | ― | 16.93% | 76.47% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | AU$3.61B | -3.16 | -890.76% | ― | 55.91% | 22.60% | |
45 Neutral | AU$30.58M | -1.41 | -165.13% | ― | 23.31% | -17.35% | |
44 Neutral | AU$144.05M | -10.00 | -70.29% | ― | ― | -257.32% | |
44 Neutral | AU$90.60M | -6.27 | -54.48% | ― | 34.20% | -23.90% | |
42 Neutral | AU$55.93M | 62.66 | 0.48% | ― | 2.23% | -263.16% |
* Healthcare Sector Average
AU:EMV
EMvision Medical Devices Ltd.
1.55
-0.57
-26.89%
AU:CMP
Compumedics Limited
0.28
-0.07
-20.00%
AU:IPD
Impedimed Limited
0.02
-0.03
-63.41%
AU:CYC
Cyclopharm Limited
0.75
-0.40
-34.78%
AU:ARX
Aroa Biosurgery Ltd
0.57
0.15
35.71%
AU:4DX
4DMedical Ltd
6.28
6.01
2225.93%
EMvision Medical Devices Ltd. Corporate Events
S&P Dow Jones Revises March 2026 All Ordinaries Rebalance
Mar 10, 2026
SP Dow Jones Indices has updated its March 2026 quarterly rebalance for the All Ordinaries, reversing the previously announced inclusion of African Gold Limited and the removal of American Rare Earths Limited. The index will instead see a range of...
S&P Dow Jones Indices Unveils March 2026 S&P/ASX Rebalance
Mar 6, 2026
SP Dow Jones Indices has announced changes to its SP/ASX equity benchmarks following the March quarterly review, reshaping the composition of the main Australian indices across the large-, mid-, and small-cap segments. The rebalance reflects shift...
EMVision Issues 1H26 Presentation with Emphasis on Risks and Forward-Looking Uncertainty
Feb 22, 2026
EMVision Medical Devices has released its 1H26 presentation, outlining information prepared for investors about the company and its activities, accompanied by extensive legal disclaimers. The document emphasises that the material is informational ...
EMvision Issues New Unquoted Options and Performance Rights Under Incentive Plan
Feb 6, 2026
EMvision Medical Devices has issued 400,000 unquoted options exercisable at $2.68 and expiring on 6 August 2029, along with 100,000 unquoted performance rights expiring on 6 February 2031, under its employee incentive scheme. The move modestly inc...
EMVision Advances emu™ Brain Scanner Trials With Growing Global Stroke Hospital Network
Jan 27, 2026
EMVision reported strong progress across its clinical programs for the emu™ brain scanner, with seven leading stroke hospitals in the US and Australia now actively recruiting patients in its pivotal validation trial and an additional Mount S...
EMvision Options Lapse, Simplifying Capital Structure
Jan 2, 2026
EMvision Medical Devices has notified the ASX that 2,550,000 listed options (EMVAP), which were exercisable at $2.25 and due to expire on 31 December 2025, have lapsed without being exercised or converted, effective 31 December 2025. The expiry of...
EMvision Director’s 300,000 Options Lapse at Expiry Without Exercise
Jan 2, 2026
EMvision Medical Devices Ltd has disclosed a change in director John Keep’s interests following the expiry and lapse of 300,000 unlisted options exercisable at $2.25 that were held through Glensburg Pty Ltd as trustee for the Tyto Corporatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.